S100A9 and COVID-19: In a clinical setting involving 48 subjects, the expression of TLR4 and its downstream signaling molecules as well as S100A9 (TLR4 ligand) were significantly upregulated in PBMCs from severe COVID-19 patients as compared to those from healthy controls.